Jefferies Upgrades Regeneron Pharmaceuticals to Buy

Loading...
Loading...
Jefferies & Company has upgraded Regeneron Pharmaceuticals
REGN
from Hold to Buy and has raised the price target from $66 to $75.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesPrice TargetPre-Market OutlookAnalyst RatingsJefferies & Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...